Targeting CD117 on hematopoietic stem and progenitor cells impairs CAR T cell activity
Molecular Therapy · 2025
DOI: 10.1016/j.ymthe.2025.05.033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2025. Verfasst von Rubina Thomas und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO 63110, USA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cells, Proto-Oncogene Proteins c-kit, Receptors, Chimeric Antigen, Immunotherapy, Adoptive. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health, National Institutes of Health National Cancer Institute.
Abstract (Originalsprache)
CD117 is a cell-surface receptor expressed on hematopoietic stem and progenitor cells and acute myeloid leukemia (AML), and thus CD117-targeting chimeric antigen receptor T cells (CART117) can function as both conditioning for hematopoietic stem cell transplantation and a therapy for AML. We developed human and mouse CART117 to evaluate the safety and feasibility of targeting CD117 in preclinical mouse models. Human CART117 had potent anti-tumor activity while also mediating significant hematopoietic toxicity in a humanized mouse model. Murine CART117 (mCART117) led to systemic and hematopoietic toxicity without anti-leukemic benefit in immunocompetent C57BL/6 mice. Intriguingly, mCART117 was able to eliminate CD117+ cells in the spleen but not in the bone marrow (BM). Of note, proliferation of BM CD117+ cells in response to lymphodepleting chemotherapy amplified mCART117-mediated systemic toxicity. Alternative lymphodepletion with radiation ameliorated the systemic toxicity of mCART117 but did not improve anti-leukemic efficacy. Immunodeficient mice given mCART117 in the absence of lymphodepletion died from severe pancytopenia, and this effect was recapitulated by regulatory T cell depletion in immunocompetent mice. Increasing CD117 expression on AML improved the anti-leukemic efficacy and toxicity profile of mCART117. In conclusion, mCART117 anti-leukemic activity is impaired in immunocompetent mice when CD117 is expressed at physiological levels on AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO 63110, USA.
- Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO 63110, USA. Electronic address: miriamykim@wustl.edu.
Förderung
- NCI NIH HHS
- National Institutes of Health
- National Institutes of Health National Cancer Institute
Zitieren
APA
Thomas, R., Ritchey, J. K., DiPersio, J. F., & Kim, M. Y. (2025). Targeting CD117 on hematopoietic stem and progenitor cells impairs CAR T cell activity. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2025.05.033
Vancouver
Thomas R, Ritchey JK, DiPersio JF, Kim MY. Targeting CD117 on hematopoietic stem and progenitor cells impairs CAR T cell activity. Molecular Therapy. 2025. doi:10.1016/j.ymthe.2025.05.033
BibTeX
@article{Thomas2025,
author = {Thomas, Rubina and Ritchey, Julie K and DiPersio, John F and Kim, Miriam Y},
title = {Targeting CD117 on hematopoietic stem and progenitor cells impairs CAR T cell activity},
journal = {Molecular Therapy},
year = {2025},
doi = {10.1016/j.ymthe.2025.05.033}
}
EUVIMED